VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
SNGX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
SNGXSoligenix, Inc.
$0.25$4M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksSNGXFinancials

Soligenix, Inc. (SNGX) Income Statement

30Y historyFree accessUpdated daily

Revenue generation remains effectively dormant with zero product sales reported for the majority of the last ten quarters, while R&D expenses continue to drive quarterly net losses as high as $3.2 million.

Income StatementBalance SheetCash FlowRatios

SNGX Income Statement

Annual statement

SNGX Income Statement

Soligenix, Inc. (SNGX) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue0000250K33.35K1.93M3.22M5.24M5.43M10.45M8.77M7.04M3.22M3.15M7.66M1.95M2.82M2.31M1.26M2.31M3.08M997.48K83.82K0000200K100K0
Revenue Growth %----100%649.6%-98.27%-39.96%-38.64%-3.52%-48.01%19.17%24.49%118.46%2.51%-58.96%293.38%-30.82%21.9%83.62%-45.61%-24.8%208.38%1090.07%-----100%100%--
Cost of Goods Sold3.19K0119.37K742.05K550.82K728.64K1.82M3.57M4.6M4.31M8.43M6.88M5.31M2.54M2.59M2.11M1.64M1.48M1.89M943.38K1.97M2.07M936.64K76.2K00-157K-1.41M-1.7M-500K0
COGS % of Revenue----220.33%2184.76%94.32%110.94%87.73%79.34%80.72%78.49%75.45%78.91%82.45%27.51%84.09%52.7%81.64%74.99%84.95%67.2%93.9%90.91%-----850%-500%-
Gross Profit-3.19K0-119.37K-742.05K-300.82K-695.29K109.58K-351.78K643.73K1.12M2.02M1.89M1.73M679.87K551.54K5.55M309.23K1.33M423.83K314.63K347.95K1.01M60.85K7.62K00156.86K1.41M1.9M600K0
Gross Margin %-----120.33%-2084.76%5.68%-10.94%12.28%20.66%19.28%21.51%24.55%21.09%17.54%72.49%15.87%47.3%18.35%25.01%15.04%32.8%6.1%9.09%----950%600%-
Gross Profit Growth %-100%83.91%-146.67%56.73%-734.48%131.15%-154.65%-42.63%-44.32%6.84%9.08%154.31%23.27%-90.07%1696.42%-76.78%214.27%34.71%-9.57%-65.52%1558.28%698.5%---100%-88.86%-25.89%216.67%--
Operating Expenses9.83M11.85M9.32M6.96M13.94M12.4M18.7M10.19M8.43M8.03M7.72M9M8.49M7.84M5.24M8.52M8.19M7.38M3.88M6.64M8.55M5.84M5.98M5.23M4.44M14.63M3.21M6.48M8.3M3.8M1.26M
OpEx % of Revenue----5575.23%37191.3%968.44%316.87%160.79%147.88%73.93%102.6%120.56%243.05%166.68%111.12%420.33%262.22%167.97%527.98%369.52%189.99%599.31%6245.15%----4150%3800%-
Selling, General & Admin4.44M4.36M4.22M4.48M6.69M5.01M4.33M3.48M2.95M3.21M3.43M3.6M3.4M2.77M2.63M2.24M2.5M2.86M2.33M3.54M3.11M2.16M2.32M2.51M1.97M1.97M2.1M3.05M3.5M1.5M317.24K
SG&A % of Revenue----2677.16%15018.25%224.23%108.25%56.33%59.08%32.82%41.02%48.33%85.76%83.72%29.26%128.49%101.56%100.74%281.56%134.5%70.32%232.69%2988.74%----1750%1500%-
Research & Development5.4M7.49M5.22M3.31M7.94M8.19M14.8M8.12M6.75M5.51M4.3M5.4M5.09M5.07M2.61M6.27M5.68M4.52M1.73M3.1M4.62M3.68M3.66M2.73M2.47M2.47M956.74K2.03M3.1M1.8M906.46K
R&D % of Revenue----3177.64%24544.54%766.43%252.6%128.81%101.38%41.11%61.59%72.23%157.29%82.96%81.86%291.79%160.62%75.06%246.42%199.74%119.67%366.62%3256.42%----1550%1800%-
Other Operating Expenses00-119.37K-839.36K-698.91K-790.92K-428.91K-1.41M-1.28M-683K0000000000816.3K0002.99M12.15M156.86K1.41M1.7M500K0
Operating Income-9.83M-11.85M-9.44M-7.7M-14.24M-13.1M-18.59M-10.54M-9.06M-7.59M-5.71M-7.11M-10.76M-7.16M-4.69M-2.96M-7.88M-6.05M-3.46M-6.33M-8.2M-4.83M-5.92M-5.23M-14.63M-14.63M-3.06M-5.08M-6.5M-3.2M-1.26M
Operating Margin %-----5695.56%-39276.06%-962.77%-327.8%-172.85%-139.8%-54.65%-81.09%-152.79%-221.99%-149.16%-38.63%-404.41%-214.88%-149.61%-502.94%-354.52%-157.18%-593.19%-6236.06%-----3250%-3200%-
Operating Income Growth %--25.49%-22.62%45.94%-8.7%29.52%-76.33%-16.36%-19.29%-32.99%19.69%33.93%-50.36%-52.57%-58.48%62.43%-30.19%-75.09%45.38%22.84%-69.6%18.29%-13.2%64.26%0%-378.1%39.74%21.91%-103.13%-153.37%-
EBITDA-9.83M-11.84M-9.43M-7.69M-14.21M-13.06M-18.52M-10.49M-9.01M-7.53M-5.62M-6.86M-10.52M-6.93M-4.46M-2.73M-7.69M-5.88M-3.31M-6.21M-8.06M-4.64M-5.61M-5M-14.28M-14.44M-2.9M-3.67M-4.8M-2.7M-1.06M
EBITDA Margin %-----5685.74%-39173.64%-959.53%-326.11%-172.01%-138.54%-53.79%-78.27%-149.3%-214.86%-141.82%-35.68%-394.88%-208.64%-143.15%-493.44%-348.59%-150.87%-562.87%-5966.26%-----2400%-2700%-
EBITDA Growth %20.5%-25.53%-22.65%45.89%-8.8%29.47%-76.65%-16.32%-19.79%-33.9%18.11%34.74%-51.8%-55.3%-63.15%64.46%-30.92%-77.68%46.73%23.01%-73.74%17.34%-12.27%64.98%1.09%-397.44%20.88%23.58%-77.78%-155.07%-
D&A (Non-Cash Add-back)4.29K3.22K5.81K6.55K24.56K34.16K62.37K54.45K44.06K68.56K89.93K247.46K245.79K230.07K230.63K226.03K185.7K175.6K149.18K119.56K137.04K194.28K302.45K226.14K345.5K188.53K156.86K1.41M1.7M500K204.46K
EBIT-9.76M-11.59M-9.46M-7.67M-14.13M-12.51M-18.51M-10.11M-9.06M-7.59M-5.71M-7.11M-6.76M-7.16M-4.69M-2.96M-7.63M-6.03M-3.46M-6.33M-8.2M-4.83M-5.85M-5.23M-14.67M-14.67M-3.06M-5.08M-6.5M-3.2M-1.26M
Net Interest Income-13.6K270.17K213.97K-49.13K-822.61K-904.5K-10.88K148.97K158.57K29.91K2.22K-8.02K1.31K1.96K6.2K7.44K11.33K19.24K33.8K164.85K41.51K114.79K66.54K28.71K141.52K459.87K747.07K0000
Interest Income-13.6K270.17K213.97K0000148.97K159.01K29.91K2.22K01.31K1.96K6.2K7.44K12.07K21.92K37.07K164.85K41.51K114.79K66.54K28.71K105.68K424.03K747.07K0000
Interest Expense00049.13K822.61K904.5K10.88K00008.02K00007422.68K3.28K00000-35.84K-35.84K00000
Other Income/Expense502.03K258.48K763.81K-210.59K-714.37K-316.75K61.09K574.75K159.01K29.91K1.93M-1.21M3.44M-3.65M6.2K7.44K246.03K16.84K33.8K162.44K-1.76M114.79K45.54K-61.65K-5.92K-5.92K-2.43M-2.86M-15.2M200K74.85K
Pretax Income-9.33M-11.59M-8.68M-7.91M-14.95M-13.42M-18.53M-9.97M-8.9M-7.56M-3.78M-8.32M-7.32M-10.81M-4.68M-2.95M-7.63M-6.05M-3.42M-6.33M-8.16M-4.72M-5.92M-5.29M-14.63M-14.63M-5.49M-7.94M-21.6M-3M-1.19M
Pretax Margin %-----5981.31%-40225.83%-959.6%-309.93%-169.81%-139.25%-36.14%-94.89%-103.99%-335.27%-148.93%-38.54%-391.79%-214.99%-148.14%-503.02%-352.92%-153.45%-593.19%-6309.62%-----10800%-3000%-
Income Tax-506.62K-506.62K-409.11K-1.77M-1.15M-864.74K-836.89K-610.68K0-417K-530K-489K-617K-750K-521K-574K-246K-16.84K-33.8K-162K-36.2K0-45.54K0-965K5.92K1.74M2.42M15.4M00
Effective Tax Rate %5.43%4.37%4.72%22.35%7.72%6.45%4.52%6.13%0%5.51%14.04%5.88%8.42%6.94%11.12%19.44%3.22%0.28%0.99%2.56%0.44%0%0.77%0%6.6%-0.04%-31.63%-30.55%-71.3%0%0%
Net Income-8.83M-11.08M-8.27M-6.14M-13.8M-12.55M-17.69M-9.36M-8.9M-7.15M-3.25M-7.83M-6.71M-10.06M-4.16M-2.38M-7.39M-6.03M-3.42M-6.17M-8.16M-4.72M-5.87M-5.29M-4.97M-14.63M-4.8M-7.5M-21.8M-3.2M-1.19M
Net Margin %-----5519.34%-37632.97%-916.25%-290.94%-169.81%-131.57%-31.06%-89.31%-95.23%-312%-132.37%-31.05%-379.21%-214.28%-148.14%-490.06%-352.92%-153.45%-588.68%-6309.62%-----10900%-3200%-
Net Income Growth %22.96%-34.04%-34.62%55.5%-9.94%29.04%-89.07%-5.12%-24.53%-120.25%58.56%-16.76%33.32%-141.63%-74.99%67.79%-22.42%-76.33%44.49%24.48%-72.94%19.62%-11.03%-6.49%66.06%-205.07%36.06%65.59%-581.25%-169.36%-
Net Income (Continuing)-8.83M-11.08M-8.27M-6.14M-13.8M-12.55M-17.69M-9.36M-8.9M-7.15M-3.25M-7.83M-6.71M-10.06M-4.16M-2.38M-7.39M-6.03M-3.42M-6.17M-8.16M-4.72M-5.87M-5.29M-4.97M-14.63M-4.8M-7.5M-21.8M-3.2M-1.19M
Discontinued Operations0000000000000000000000000000000
Minority Interest00000000000000000000000000008.4M00
EPS (Diluted)-0.40-2.14-4.98-12.66-76.89-75.06-154.45-115.88-162.09-278.40-321.60-721.04-714.19-1560.00-888.00-528.00-1752.00-1920.00-1440.00-3360.00-6240.00-4320.00-7285.45-8634.50-662.23-3263.70-23312.80-39225.14-6568.24-15458.94-703.37
EPS Growth %79.71%57.03%60.66%83.53%-2.44%51.4%-33.28%28.51%41.78%13.43%55.4%-0.96%54.22%-75.68%-68.18%69.86%8.75%-33.33%57.14%46.15%-44.44%40.7%15.62%-1203.85%79.71%86%40.57%-497.19%57.51%-2097.84%-
EPS (Basic)--2.14-4.98-12.66-76.96-67.54-154.45-115.88-162.09-278.40-223.20-721.04-714.19-1560.00-888.00-528.00-1752.00-1920.00-1440.00-3360.00-6240.00-4320.00-7285.45-8634.50-662.23-3263.70-23312.80-39225.14-6568.24-15458.94-703.37
Diluted Shares Outstanding22.15M5.19M1.66M484.88K179.46K185.8K114.53K80.73K54.91K25.6K14.93K10.86K9.39K6.44K74.24K73.05K67.47K3.49K33.96K30.23K21.25K16.57K13.54K9.73K7.5K4.48K4.06K3.58K3.32K1.05K1.69K
Basic Shares Outstanding22.15M5.19M1.66M484.88K179.29K185.8K114.53K80.73K54.91K25.6K14.51K10.86K9.39K6.44K74.24K73.05K67.47K3.49K33.96K30.23K21.25K16.57K13.54K9.73K7.5K4.48K4.06K3.58K3.32K1.05K1.69K
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Regulatory and liquidity insolvency

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Generation Remains Effectively Dormant

As indicated by the company's financial filings, Soligenix has generated zero product revenue for the majority of the last ten quarters, with the most recent period showing no top-line inflows, underscoring a total reliance on intermittent, non-recurring government grant funding rather than sustainable commercial market activity.

The absence of consistent revenue streams suggests that the company remains in a pre-commercial state, with no clear evidence of a transition toward product-led growth. Investors should monitor the reliance on government procurement cycles, which appear to be the only potential, albeit unpredictable, source of future capital inflows.

Clinical Trial Spending Drives Burn

Based on reported income statements, R&D expenses have consistently fluctuated between $0.5 million and $2.7 million per quarter, reflecting the capital-intensive nature of late-stage clinical trials that currently consume the entirety of the company's available financial resources without generating any offsetting commercial revenue or margin.

The cost structure is almost entirely variable based on clinical trial milestones, leaving little room for operational efficiency improvements. This high-fixed-cost model necessitates constant capital infusions, as the current expense profile is untethered from any revenue-generating activities that could otherwise mitigate the ongoing cash burn.

Dilution Risks Obscure Earnings Quality

According to historical financial data, the company's net losses have remained persistent, with quarterly deficits ranging from $1.6 million to $3.2 million, a trend that is further complicated by stock-based compensation expenses that continue to dilute existing shareholders despite the lack of operational progress.

The quality of earnings is effectively non-existent given the recurring net losses and the reliance on equity-based incentives to manage cash outflows. The persistent negative EPS suggests that shareholders are bearing the full weight of the company's R&D-heavy business model without the benefit of operational leverage.

Binary Risk Outweighs Platform Potential

While proponents may point to the potential of the ThermoVax platform, the income statement reveals a company struggling to maintain a $7.9 million cash runway, suggesting that the risk of a dilutive financing event is significantly higher than the probability of near-term commercial success.

Short-term observers should focus on the widening gap between R&D spending and the lack of regulatory milestones, which may indicate that the company's pipeline is not advancing at a pace sufficient to avoid further capital raises. The lack of a commercial floor makes the company highly susceptible to any negative regulatory developments.

SNGX — Frequently Asked Questions

Quick answers to the most common questions about buying SNGX stock.

What was Soligenix, Inc.'s (SNGX) revenue in 2025?

For fiscal year 2025, Soligenix, Inc. (SNGX) reported total revenue of $0.0M.

Is Soligenix, Inc. (SNGX) profitable?

Soligenix, Inc. (SNGX) reported a net loss of $11.1M for the fiscal year ending 2025.